COBO

Cobo Therapeutics is a biotechnology company focused on overcoming the endosomal entrapment barrier to enable the cytosolic delivery of large therapeutic biologics. The company's proprietary platform is designed to facilitate the direct entry of proteins, mRNA, and gene-editing tools into the cell's cytoplasm, unlocking previously inaccessible intracellular targets. By bypassing traditional endocytic pathways, Cobo aims to improve the efficacy and safety of next-generation therapies for oncology and rare genetic disorders. Founded by leading researchers from MIT and the Broad Institute, the company is currently advancing its delivery technology through pre-clinical optimization and payload validation.